Umman Berrin
Department of Cardiology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
Anadolu Kardiyol Derg. 2006 Apr;6 Suppl 1:13-9.
The pathophysiology of acute coronary syndromes involves plaque rupture or fissure with platelet activation and aggregation. Antiplatelet therapy is a cornerstone in the management of unstable angina and non-ST elevation myocardial infarction. Three classes of antiplatelet drugs have been found useful in the management of these patients: aspirin, thienopyridines and glycoprotein IIb/IIIa antagonists. There is a great amount of interpatient variability in response to these antiplatelet agents, and this variability may affect outcomes. It is needed to prescribe appropriate antiplatelet therapies according to potential benefit in reducing death and cardiovascular events vs the bleeding risks these agents cause. Antiplatelet drugs are the subjects of continued intensive investigation.
急性冠状动脉综合征的病理生理学涉及斑块破裂或裂隙，伴有血小板活化和聚集。抗血小板治疗是不稳定型心绞痛和非ST段抬高型心肌梗死管理的基石。已发现三类抗血小板药物对这些患者的管理有用：阿司匹林、噻吩吡啶类和糖蛋白IIb/IIIa拮抗剂。患者对这些抗血小板药物的反应存在很大的个体差异，这种差异可能会影响治疗结果。需要根据降低死亡和心血管事件的潜在益处与这些药物引起的出血风险来开具适当的抗血小板治疗方案。抗血小板药物是持续深入研究的对象。
